Currently no treatment option is available for five percent of patients suffering from chronic myelogenous leukemia, since they have developed resistance to conventional medications. Researchers have investigated the combined action of two different compounds against this form of leukemia, and can now explain at the atomic level how both substances alter the structure of an enzyme and how their combination potentially can overcome drug resistance.

Source: Interaction between two leukemia drugs explained


David Cottle

UBB Owner & Administrator